Hannerieke (J.M.P.) van den Hout

Dr. Hannerieke (J.M.P.) van den Hout

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2018 in Developmental Medicine & Child Neurology
Verified
Journal Article
Open access
PDF file
BEBerendine J Ebbink
Berendine J Ebbink
EPEsther Poelman
Esther Poelman
FAFemke K Aarsen
Femke K Aarsen
IPIris Plug
Iris Plug
LRLuc Régal
Luc Régal
HHHannerieke (J.M.P.) van den Hout
Hannerieke (J.M.P.) van den Hout
Aim: To examine the long‐term consequences of glycogen storage in the central nervous system (CNS) for classic infantile Pompe disease using enzyme replacement therapy.Method: Using neuropsychological tests and brain magnetic resonance imaging (MRI), we prospectively assessed a cohort of 11 classic infantile Pompe patients aged up to 17 years.Results: From approximately age 2 years onwards, brain MRI showed involvement of the periventricular white matter and centrum semiovale. After 8 years of age, additional white‐matter abnormalities occurred in the corpus callosum, internal and external capsule, and subcortical areas. From 11 years of age, white‐matter abnormalities were also found in the brainstem. Although there seemed to be a characteristic pattern of involvement over time, there were considerable variations between patients, reflected by variations in neuropsychological development. Cognitive development ranged from stable and normal to declines that lead to intellectual disabilities.Interpretation: As treatment enables patients with classic infantile Pompe disease to reach adulthood, white‐matter abnormalities are becoming increasingly evident, affecting the neuropsychological development. Therefore, we advise follow‐up programs are expanded to capture CNS involvement in larger, international patient cohorts, to incorporate our findings in the counselling of parents before the start of treatment, and to include the brain as an additional target in the development of next‐generation therapeutic strategies for classic infantile Pompe disease.What this paper adds: In our long‐term survivors treated intravenously with enzyme replacement therapy, we found slowly progressive symmetric white‐matter abnormalities. Cognitive development varied from stable and normal to declines towards intellectual disabilities.

1 January 2022 in The Lancet Child & Adolescent Health
Verified
Journal Article
Closed access
IDImke Anne Maartje Ditters
Imke Anne Maartje Ditters
HHHidde Harmen Huidekoper
Hidde Harmen Huidekoper
MKMichelle Elisabeth Kruijshaar
Michelle Elisabeth Kruijshaar
DRDimitris Rizopoulos
Dimitris Rizopoulos
AHAndreas Hahn
Andreas Hahn
DDDries Dobbelaere
Dries Dobbelaere

29 March 2016 in Neurology
Verified
Journal Article
Closed access
PDF file
BEBerendine J. Ebbink
Berendine J. Ebbink
EPEsther Poelman
Esther Poelman
IPIris Plug
Iris Plug
MLMaarten H. Lequin
Maarten H. Lequin
PDPieter A. van Doorn
Pieter A. van Doorn
HHHannerieke (J.M.P.) van den Hout
Hannerieke (J.M.P.) van den Hout

22 March 2019 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
EPE. Poelman
E. Poelman
MHM. Hoogeveen-Westerveld
M. Hoogeveen-Westerveld
HHHannerieke (J.M.P.) van den Hout
Hannerieke (J.M.P.) van den Hout
RBR. G. M. Bredius
R. G. M. Bredius
ALA. C. Lankester
A. C. Lankester
APA. T. van der Ploeg
A. T. van der Ploeg
To evaluate whether immunomodulation can eliminate high sustained antibody levels, and thereby improve clinical outcome in classic infantile Pompe patients receiving enzyme replacement therapy (ERT) with recombinant human alpha-glucosidase (rhGAA). Three patients (two cross-reactive immunologic material (CRIM) negative) with high sustained antibodies received a three-week treatment protocol with Rituximab and Bortezomib, followed by daily Rapamycin and monthly IVIG. Patients received 40 mg/kg/week rhGAA. Antibody titers were measured using ELISA. Neutralizing effects on cellular uptake were determined. Clinical efficacy was measured in terms of (ventilator-free) survival, reduction in left ventricular mass index (LVMI) and improvement in motor function. Before immunomodulation anti-rhGAA antibody titers ranged from 1:156,250 to 1:781,250 and at last assessment from 1:31,250 to 1:156,250. Neutralizing effects of anti-rhGAA antibody titers (observed in two patients) disappeared. Infusion-associated reactions were no longer present. Immunomodulation resulted in substantial increases of aspartate transaminase, alanine transaminase, and creatine kinase levels. The two CRIM-negative patients who could walk at start of immunomodulation maintained their ability to walk; the patient who had lost this ability did not regain it. To some extent, the immunomodulation protocol used in our study reduced antibody titers, but it did not eliminate them. Overall, there have been few reports on secondary immunomodulation, and various protocols have been applied. Future research should seek to identify the most successful immunomodulation protocol in patients with high sustained titers.

8 May 2023 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
IDImke Anne Maartje Ditters
Imke Anne Maartje Ditters
NBNadine A. M. E. van der Beek
Nadine A. M. E. van der Beek
EBEsther Brusse
Esther Brusse
APAns T. van der Ploeg
Ans T. van der Ploeg
HHHannerieke (J.M.P.) van den Hout
Hannerieke (J.M.P.) van den Hout
HHHidde Huidekoper
Hidde Huidekoper
Background: Pompe disease is a lysosomal storage disease treated with life-long enzyme replacement therapy (ERT). Home-based ERT has been provided in the Netherlands since 2008 because it diminishes the burden of treatment, increases patient flexibility and autonomy, and is thus a more patient-centred approach to ERT. Methods: All Dutch Pompe patients receiving alglucosidase alfa infusions at home were approached to participate in a questionnaire to validate the safety of home-based ERT. Prospective data on symptoms occurring during or within 48 h after infusion and retrospective data on infusion associated reactions (IARs) in the last three months were collected four times during one year. Results: In total, 116 out of 120 eligible patients (17 classic infantile, 2 atypical infantile, 15 childhood onset and 82 adult) filled out 423 questionnaires (response rate: 88.1%). Symptoms during or after infusion were reported 27 times in 17 patients. Fatigue was the most commonly reported health complaint (in 9.5% of patients). Four health complaints were judged to be IARs and reported to the Erasmus MC University Medical Center. None of the IARs reported in this study warranted emergency clinical care. Conclusions: Our data demonstrate that home-based ERT in Pompe disease can be safely implemented as few, mostly mild, symptoms were reported during or after infusion. Insights from this study can be used as a base for implementing home-based ERT in other countries and to further optimize patient care, as unreported mild symptoms do not pose a health risk but may still be relevant to the patient.

16 June 2023 in BioDrugs
Verified
Journal Article
Open access
PDF file
IDImke Anne Maartje Ditters
Imke Anne Maartje Ditters
HKHarmke A. van Kooten
Harmke A. van Kooten
NBNadine A. M. E. van der Beek
Nadine A. M. E. van der Beek
JHJacqueline F. Hardon
Jacqueline F. Hardon
GIGamida Ismailova
Gamida Ismailova
HHHidde Huidekoper
Hidde Huidekoper
Background Enzyme replacement therapy (ERT) with alglucosidase alfa is the treatment for patients with Pompe disease, a hereditary metabolic myopathy. Home-based ERT is unavailable in many countries because of the boxed warning alglucosidase alfa received due to the risk of infusion-associated reactions (IARs). Since 2008, home infusions have been provided in The Netherlands. Objectives This study aimed to provide an overview of our experience with home-based infusions with alglucosidase alfa in adult Pompe patients, focusing on safety, including management of IARs. Method We analysed infusion data and IARs from adult patients starting ERT between 1999 and 2018. ERT was initially given in the hospital during the first year. Patients were eligible for home treatment if they were without IARs for multiple consecutive infusions and if a trained home nurse, with on-call back-up by a doctor, was available. The healthcare providers graded IARs. Results We analysed data on 18,380 infusions with alglucosidase alfa in 121 adult patients; 4961 infusions (27.0%) were given in hospital and 13,419 (73.0%) were given at home. IARs occurred in 144 (2.9%) hospital infusions and 113 (0.8%) home infusions; 115 (79.9% of 144) IARs in hospital and 104 (92.0% of 113) IARs at home were mild, 25 IARs (17.4%) in hospital and 8 IARs (7.1%) at home were moderate, and very few severe IARs occurred (4 IARs in hospital [2.8%] and 1 IAR at home [0.9%]). Only one IAR in the home situation required immediate clinical evaluation in the hospital. Conclusion Given the small numbers of IARs that occurred with the home infusions, of which only one was severe, we conclude that alglucosidase alfa can be administered safely in the home situation, provided the appropriate infrastructure is present.